GenomeNet

Database: UniProt
Entry: P35462
LinkDB: P35462
Original site: P35462 
ID   DRD3_HUMAN              Reviewed;         400 AA.
AC   P35462; A1A4V5; Q4VBM8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 3.
DT   27-MAR-2024, entry version 215.
DE   RecName: Full=D(3) dopamine receptor {ECO:0000305};
DE   AltName: Full=Dopamine D3 receptor;
GN   Name=DRD3 {ECO:0000312|HGNC:HGNC:3024};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2129115;
RA   Giros B., Martres M.-P., Sokoloff P., Schwartz J.-C.;
RT   "Gene cloning of human dopaminergic D3 receptor and identification of its
RT   chromosome.";
RL   C. R. Acad. Sci. III, Sci. Vie 311:501-508(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANT SER-9.
RC   TISSUE=Brain;
RX   PubMed=8415635; DOI=10.1073/pnas.90.19.8942;
RA   Schmauss C., Haroutunian V., Davis K.L., Davidson M.;
RT   "Selective loss of dopamine D3-type receptor mRNA expression in parietal
RT   and motor cortices of patients with chronic schizophrenia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:8942-8946(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=7961889; DOI=10.1016/s0021-9258(19)62033-8;
RA   Liu K., Bergson C., Levenson R., Schmauss C.;
RT   "On the origin of mRNA encoding the truncated dopamine D3-type receptor
RT   D3nf and detection of D3nf-like immunoreactivity in human brain.";
RL   J. Biol. Chem. 269:29220-29226(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-9.
RA   Fishburn C.S., Park B.-H., Fuchs S.;
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-9.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-9.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INVOLVEMENT IN SCZD, AND VARIANT SER-9.
RX   PubMed=1362221; DOI=10.1136/jmg.29.12.858;
RA   Crocq M.A., Mant R., Asherson P., Williams J., Hode Y., Mayerova A.,
RA   Collier D., Lannfelt L., Sokoloff P., Schwartz J.C.;
RT   "Association between schizophrenia and homozygosity at the dopamine D3
RT   receptor gene.";
RL   J. Med. Genet. 29:858-860(1992).
RN   [9]
RP   INVOLVEMENT IN SCZD, AND VARIANT SER-9.
RX   PubMed=9514583;
RX   DOI=10.1002/(sici)1096-8628(19980207)81:1<24::aid-ajmg5>3.0.co;2-n;
RA   Spurlock G., Williams J., McGuffin P., Aschauer H.N., Lenzinger E.,
RA   Fuchs K., Sieghart W.C., Meszaros K., Fathi N., Laurent C., Mallet J.,
RA   Macciardi F., Pedrini S., Gill M., Hawi Z., Gibson S., Jazin E.E.,
RA   Yang H.T., Adolfsson R., Pato C.N., Dourado A.M., Owen M.J.;
RT   "European multicentre association study of schizophrenia: a study of the
RT   DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms.";
RL   Am. J. Med. Genet. 81:24-28(1998).
RN   [10]
RP   INTERACTION WITH PALM.
RX   PubMed=16386234; DOI=10.1016/j.abb.2005.10.027;
RA   Basile M., Lin R., Kabbani N., Karpa K., Kilimann M., Simpson I.,
RA   Kester M.;
RT   "Paralemmin interacts with D3 dopamine receptors: implications for membrane
RT   localization and cAMP signaling.";
RL   Arch. Biochem. Biophys. 446:60-68(2006).
RN   [11]
RP   PHOSPHORYLATION BY GRK4, SUBCELLULAR LOCATION, INTERACTION WITH GRK4, AND
RP   FUNCTION.
RX   PubMed=19520868; DOI=10.1074/jbc.m109.003665;
RA   Villar V.A.M., Jones J.E., Armando I., Palmes-Saloma C., Yu P.,
RA   Pascua A.M., Keever L., Arnaldo F.B., Wang Z., Luo Y., Felder R.A.,
RA   Jose P.A.;
RT   "G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation
RT   and function of the dopamine D3 receptor.";
RL   J. Biol. Chem. 284:21425-21434(2009).
RN   [12]
RP   INTERACTION WITH FLNA.
RX   PubMed=26460884; DOI=10.1021/acs.biochem.5b00975;
RA   Tirupula K.C., Ithychanda S.S., Mohan M.L., Naga Prasad S.V., Qin J.,
RA   Karnik S.S.;
RT   "G Protein-Coupled Receptors Directly Bind Filamin A with High Affinity and
RT   Promote Filamin Phosphorylation.";
RL   Biochemistry 54:6673-6683(2015).
RN   [13]
RP   PALMITOYLATION.
RX   PubMed=27659709; DOI=10.1016/j.bbrc.2016.09.094;
RA   Zhang X., Kim K.M.;
RT   "Palmitoylation of the carboxyl-terminal tail of dopamine D4 receptor is
RT   required for surface expression, endocytosis, and signaling.";
RL   Biochem. Biophys. Res. Commun. 479:398-403(2016).
RN   [14] {ECO:0007744|PDB:3PBL}
RP   X-RAY CRYSTALLOGRAPHY (2.89 ANGSTROMS) OF 2-221 AND 319-400 IN COMPLEX WITH
RP   THE ANTAGONIST ETICLOPRIDE, DISULFIDE BONDS, AND MEMBRANE TOPOLOGY.
RX   PubMed=21097933; DOI=10.1126/science.1197410;
RA   Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., Shi L.,
RA   Newman A.H., Javitch J.A., Cherezov V., Stevens R.C.;
RT   "Structure of the human dopamine D3 receptor in complex with a D2/D3
RT   selective antagonist.";
RL   Science 330:1091-1095(2010).
RN   [15]
RP   VARIANT SER-9.
RA   Lannfelt T., Sokoloff P., Martres M.-P., Pilon C., Giros B., Joensson E.,
RA   Sedvall G., Schwartz J.-C.;
RT   "Amino-acid substitution in the dopamine D3 receptor as useful polymorphism
RT   for investigating psychiatric disorders.";
RL   Psychiatr. Genet. 2:249-256(1992).
RN   [16]
RP   VARIANT SER-9.
RX   PubMed=9034004;
RX   DOI=10.1002/(sici)1096-8628(19970221)74:1<40::aid-ajmg9>3.0.co;2-z;
RA   Chen C.-H., Liu M.-Y., Wei F.-C., Koong F.-J., Hwu H.-G., Hsiao K.-J.;
RT   "Further evidence of no association between Ser9Gly polymorphism of
RT   dopamine D3 receptor gene and schizophrenia.";
RL   Am. J. Med. Genet. 74:40-43(1997).
RN   [17]
RP   VARIANT SER-9.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [18]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [19]
RP   VARIANT SER-9, AND INVOLVEMENT IN SUSCEPTIBILITY TO ETM1.
RX   PubMed=16650084; DOI=10.1111/j.1399-0004.2006.00600.x;
RA   Lucotte G., Lagarde J.-P., Funalot B., Sokoloff P.;
RT   "Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families.";
RL   Clin. Genet. 69:437-440(2006).
RN   [20]
RP   VARIANT SER-9, AND INVOLVEMENT IN SUSCEPTIBILITY TO ETM1.
RX   PubMed=16809426; DOI=10.1073/pnas.0508189103;
RA   Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.-P., Lucotte G.,
RA   Sokoloff P.;
RT   "A functional variant of the dopamine D3 receptor is associated with risk
RT   and age-at-onset of essential tremor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006).
CC   -!- FUNCTION: Dopamine receptor whose activity is mediated by G proteins
CC       which inhibit adenylyl cyclase. Promotes cell proliferation.
CC       {ECO:0000269|PubMed:19520868}.
CC   -!- SUBUNIT: Interacts with CLIC6 (By similarity). Interacts with GRK4
CC       (PubMed:19520868). Interacts with PALM (PubMed:16386234). Interacts
CC       with FLNA (via filamin repeat 21); increases PKA-mediated
CC       phosphorylation of FLNA (PubMed:26460884).
CC       {ECO:0000250|UniProtKB:P19020, ECO:0000269|PubMed:16386234,
CC       ECO:0000269|PubMed:19520868, ECO:0000269|PubMed:26460884}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19520868};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:19520868}. Note=Both
CC       membrane-bound and scattered in the cytoplasm during basal conditions.
CC       Receptor stimulation results in the rapid internalization and
CC       sequestration of the receptors at the perinuclear area (5 and 15
CC       minutes), followed by the dispersal of the receptors to the membrane
CC       (30 minutes). DRD3 and GRK4 co-localize in lipid rafts of renal
CC       proximal tubule cells.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=D3;
CC         IsoId=P35462-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P35462-3; Sequence=VSP_040570;
CC   -!- TISSUE SPECIFICITY: Brain.
CC   -!- PTM: Phosphorylated by GRK4 (GRK4-alpha and GRK4-gamma).
CC       {ECO:0000269|PubMed:19520868}.
CC   -!- PTM: Palmitoylated. {ECO:0000269|PubMed:27659709}.
CC   -!- DISEASE: Tremor, hereditary essential 1 (ETM1) [MIM:190300]: A common
CC       movement disorder mainly characterized by postural tremor of the arms.
CC       Head, legs, trunk, voice, jaw, and facial muscles may also be involved.
CC       The condition can be aggravated by emotions, hunger, fatigue and
CC       temperature extremes, and may cause a functional disability or even
CC       incapacitation. Inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:16650084, ECO:0000269|PubMed:16809426}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry. Glycine at position 9 results in gain
CC       of function and is associated with susceptibility to essential tremor.
CC       {ECO:0000269|PubMed:16650084, ECO:0000269|PubMed:16809426}.
CC   -!- DISEASE: Schizophrenia (SCZD) [MIM:181500]: A complex, multifactorial
CC       psychotic disorder or group of disorders characterized by disturbances
CC       in the form and content of thought (e.g. delusions, hallucinations), in
CC       mood (e.g. inappropriate affect), in sense of self and relationship to
CC       the external world (e.g. loss of ego boundaries, withdrawal), and in
CC       behavior (e.g bizarre or apparently purposeless behavior). Although it
CC       affects emotions, it is distinguished from mood disorders in which such
CC       disturbances are primary. Similarly, there may be mild impairment of
CC       cognitive function, and it is distinguished from the dementias in which
CC       disturbed cognitive function is considered primary. Some patients
CC       manifest schizophrenic as well as bipolar disorder symptoms and are
CC       often given the diagnosis of schizoaffective disorder.
CC       {ECO:0000269|PubMed:1362221, ECO:0000269|PubMed:9514583}. Note=Disease
CC       susceptibility may be associated with variants affecting the gene
CC       represented in this entry. Glycine at position 9 results in gain of
CC       function and may be a risk factor for schizophrenia.
CC       {ECO:0000269|PubMed:1362221, ECO:0000269|PubMed:9514583}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA03543.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA64369.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=C&genename=DRD3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L20469; AAA03543.1; ALT_FRAME; mRNA.
DR   EMBL; AH003061; AAA64369.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; U32499; AAA73929.1; -; mRNA.
DR   EMBL; AC092896; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79610.1; -; Genomic_DNA.
DR   EMBL; BC095510; AAH95510.1; -; mRNA.
DR   EMBL; BC128123; AAI28124.1; -; mRNA.
DR   CCDS; CCDS2978.1; -. [P35462-1]
DR   CCDS; CCDS33829.1; -. [P35462-3]
DR   PIR; A48258; A48258.
DR   PIR; A55419; A55419.
DR   PIR; G01977; G01977.
DR   RefSeq; NP_000787.2; NM_000796.5. [P35462-1]
DR   RefSeq; NP_001269492.1; NM_001282563.2. [P35462-1]
DR   RefSeq; NP_001277738.1; NM_001290809.1. [P35462-1]
DR   RefSeq; NP_387512.3; NM_033663.5. [P35462-3]
DR   RefSeq; XP_016861318.1; XM_017005829.1.
DR   PDB; 3PBL; X-ray; 2.89 A; A/B=2-221, A/B=319-400.
DR   PDB; 7CMU; EM; 3.00 A; R=1-400.
DR   PDB; 7CMV; EM; 2.70 A; R=1-400.
DR   PDB; 8IRT; EM; 2.70 A; R=1-400.
DR   PDBsum; 3PBL; -.
DR   PDBsum; 7CMU; -.
DR   PDBsum; 7CMV; -.
DR   PDBsum; 8IRT; -.
DR   AlphaFoldDB; P35462; -.
DR   EMDB; EMD-30410; -.
DR   EMDB; EMD-30411; -.
DR   EMDB; EMD-35685; -.
DR   SMR; P35462; -.
DR   BioGRID; 108148; 30.
DR   DIP; DIP-5976N; -.
DR   IntAct; P35462; 8.
DR   MINT; P35462; -.
DR   STRING; 9606.ENSP00000373169; -.
DR   BindingDB; P35462; -.
DR   ChEMBL; CHEMBL234; -.
DR   DrugBank; DB06288; Amisulpride.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB09207; AS-8112.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB09223; Blonanserin.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB09014; Captodiame.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB11274; Dihydro-alpha-ergocryptine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB01184; Domperidone.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB11275; Epicriptine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00875; Flupentixol.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB08804; Nandrolone decanoate.
DR   DrugBank; DB05766; Norclozapine.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB12061; Pardoprunox.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB01100; Pimozide.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB12478; Piribedil.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB06454; Sarizotan.
DR   DrugBank; DB00391; Sulpiride.
DR   DrugBank; DB06477; Sumanirole.
DR   DrugBank; DB09289; Tianeptine.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P35462; -.
DR   GuidetoPHARMACOLOGY; 216; -.
DR   TCDB; 9.A.14.3.9; the g-protein-coupled receptor (gpcr) family.
DR   GlyCosmos; P35462; 4 sites, No reported glycans.
DR   GlyGen; P35462; 4 sites.
DR   iPTMnet; P35462; -.
DR   PhosphoSitePlus; P35462; -.
DR   SwissPalm; P35462; -.
DR   BioMuta; DRD3; -.
DR   DMDM; 1169206; -.
DR   PaxDb; 9606-ENSP00000373169; -.
DR   PeptideAtlas; P35462; -.
DR   ABCD; P35462; 1 sequenced antibody.
DR   Antibodypedia; 16482; 336 antibodies from 38 providers.
DR   DNASU; 1814; -.
DR   Ensembl; ENST00000295881.9; ENSP00000295881.6; ENSG00000151577.14. [P35462-3]
DR   Ensembl; ENST00000383673.5; ENSP00000373169.2; ENSG00000151577.14. [P35462-1]
DR   Ensembl; ENST00000460779.5; ENSP00000419402.1; ENSG00000151577.14. [P35462-1]
DR   Ensembl; ENST00000467632.5; ENSP00000420662.1; ENSG00000151577.14. [P35462-1]
DR   GeneID; 1814; -.
DR   KEGG; hsa:1814; -.
DR   MANE-Select; ENST00000383673.5; ENSP00000373169.2; NM_000796.6; NP_000787.2.
DR   AGR; HGNC:3024; -.
DR   CTD; 1814; -.
DR   DisGeNET; 1814; -.
DR   GeneCards; DRD3; -.
DR   HGNC; HGNC:3024; DRD3.
DR   HPA; ENSG00000151577; Tissue enriched (brain).
DR   MalaCards; DRD3; -.
DR   MIM; 126451; gene.
DR   MIM; 181500; phenotype.
DR   MIM; 190300; phenotype.
DR   neXtProt; NX_P35462; -.
DR   OpenTargets; ENSG00000151577; -.
DR   Orphanet; 862; NON RARE IN EUROPE: Hereditary essential tremor.
DR   PharmGKB; PA27479; -.
DR   VEuPathDB; HostDB:ENSG00000151577; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000159661; -.
DR   InParanoid; P35462; -.
DR   OMA; QINSTCG; -.
DR   OrthoDB; 2999405at2759; -.
DR   PhylomeDB; P35462; -.
DR   TreeFam; TF334382; -.
DR   PathwayCommons; P35462; -.
DR   Reactome; R-HSA-390651; Dopamine receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SignaLink; P35462; -.
DR   SIGNOR; P35462; -.
DR   BioGRID-ORCS; 1814; 7 hits in 1154 CRISPR screens.
DR   GenomeRNAi; 1814; -.
DR   Pharos; P35462; Tclin.
DR   PRO; PR:P35462; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P35462; Protein.
DR   Bgee; ENSG00000151577; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 14 other cell types or tissues.
DR   ExpressionAtlas; P35462; baseline and differential.
DR   Genevisible; P35462; HS.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0001591; F:dopamine neurotransmitter receptor activity, coupled via Gi/Go; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0046717; P:acid secretion; ISS:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050482; P:arachidonic acid secretion; IDA:BHF-UCL.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEP:BHF-UCL.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0042417; P:dopamine metabolic process; IC:BHF-UCL.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0007612; P:learning; NAS:BHF-UCL.
DR   GO; GO:0007611; P:learning or memory; NAS:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0050883; P:musculoskeletal movement, spinal reflex action; ISS:BHF-UCL.
DR   GO; GO:0045776; P:negative regulation of blood pressure; ISS:BHF-UCL.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:BHF-UCL.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0060158; P:phospholipase C-activating dopamine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0060161; P:positive regulation of dopamine receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; IMP:BHF-UCL.
DR   GO; GO:0014059; P:regulation of dopamine secretion; ISS:BHF-UCL.
DR   GO; GO:0051584; P:regulation of dopamine uptake involved in synaptic transmission; IC:BHF-UCL.
DR   GO; GO:0043266; P:regulation of potassium ion transport; IBA:GO_Central.
DR   GO; GO:0042220; P:response to cocaine; IEP:BHF-UCL.
DR   GO; GO:0034776; P:response to histamine; IDA:BHF-UCL.
DR   GO; GO:0043278; P:response to morphine; ISS:BHF-UCL.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; ISS:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; NAS:BHF-UCL.
DR   GO; GO:0008542; P:visual learning; ISS:BHF-UCL.
DR   CDD; cd15310; 7tmA_D3_dopamine_R; 1.
DR   Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1.
DR   InterPro; IPR001620; Dopamine_D3_rcpt.
DR   InterPro; IPR000929; Dopamine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248; ADRENERGIC RECEPTOR-RELATED G-PROTEIN COUPLED RECEPTOR; 1.
DR   PANTHER; PTHR24248:SF154; D(3) DOPAMINE RECEPTOR; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00568; DOPAMINED3R.
DR   PRINTS; PR00242; DOPAMINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Receptor; Reference proteome; Schizophrenia; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..400
FT                   /note="D(3) dopamine receptor"
FT                   /id="PRO_0000069397"
FT   TOPO_DOM        1..32
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        33..55
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        56..65
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        66..88
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        89..104
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        105..126
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        127..149
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        150..170
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        171..187
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        188..209
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        210..329
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        330..351
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        352..366
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        367..386
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        387..400
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   BINDING         110
FT                   /ligand="eticlopride"
FT                   /ligand_id="ChEBI:CHEBI:188152"
FT                   /ligand_note="antagonist"
FT                   /evidence="ECO:0000269|PubMed:21097933,
FT                   ECO:0007744|PDB:3PBL"
FT   BINDING         345
FT                   /ligand="eticlopride"
FT                   /ligand_id="ChEBI:CHEBI:188152"
FT                   /ligand_note="antagonist"
FT                   /evidence="ECO:0000269|PubMed:21097933,
FT                   ECO:0007744|PDB:3PBL"
FT   BINDING         349
FT                   /ligand="eticlopride"
FT                   /ligand_id="ChEBI:CHEBI:188152"
FT                   /ligand_note="antagonist"
FT                   /evidence="ECO:0000269|PubMed:21097933,
FT                   ECO:0007744|PDB:3PBL"
FT   CARBOHYD        12
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        19
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        97
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        173
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        103..181
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:21097933, ECO:0007744|PDB:3PBL"
FT   DISULFID        355..358
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:21097933, ECO:0007744|PDB:3PBL"
FT   VAR_SEQ         287..320
FT                   /note="SPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGV -> M (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:8415635"
FT                   /id="VSP_040570"
FT   VARIANT         9
FT                   /note="G -> S (in dbSNP:rs6280)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:1362221, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:16650084, ECO:0000269|PubMed:16809426,
FT                   ECO:0000269|PubMed:9034004, ECO:0000269|PubMed:9514583,
FT                   ECO:0000269|Ref.15"
FT                   /id="VAR_003463"
FT   CONFLICT        396
FT                   /note="K -> L (in Ref. 7; AAH95510)"
FT                   /evidence="ECO:0000305"
FT   HELIX           34..56
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           58..60
FT                   /evidence="ECO:0007829|PDB:8IRT"
FT   HELIX           63..81
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           83..92
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           100..133
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           135..138
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           144..169
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   TURN            170..172
FT                   /evidence="ECO:0007829|PDB:8IRT"
FT   HELIX           186..196
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           198..222
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           322..354
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           362..384
FT                   /evidence="ECO:0007829|PDB:7CMV"
FT   HELIX           388..399
FT                   /evidence="ECO:0007829|PDB:7CMV"
SQ   SEQUENCE   400 AA;  44195 MW;  3E8426597D6C164D CRC64;
     MASLSQLSGH LNYTCGAENS TGASQARPHA YYALSYCALI LAIVFGNGLV CMAVLKERAL
     QTTTNYLVVS LAVADLLVAT LVMPWVVYLE VTGGVWNFSR ICCDVFVTLD VMMCTASILN
     LCAISIDRYT AVVMPVHYQH GTGQSSCRRV ALMITAVWVL AFAVSCPLLF GFNTTGDPTV
     CSISNPDFVI YSSVVSFYLP FGVTVLVYAR IYVVLKQRRR KRILTRQNSQ CNSVRPGFPQ
     QTLSPDPAHL ELKRYYSICQ DTALGGPGFQ ERGGELKREE KTRNSLSPTI APKLSLEVRK
     LSNGRLSTSL KLGPLQPRGV PLREKKATQM VAIVLGAFIV CWLPFFLTHV LNTHCQTCHV
     SPELYSATTW LGYVNSALNP VIYTTFNIEF RKAFLKILSC
//
DBGET integrated database retrieval system